Advanced search
Publication Cover
Hematology Volume 27, 2022 - Issue 1
Submit an article Journal homepage
1,564
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Clinical risk factors for patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation

Haruka Teshigawara-Tanabea Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan;b Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, JapanORCID Iconhttps://orcid.org/0000-0002-3887-9001
ORCID Icon,
Maki Hagiharab Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4928-2147
ORCID Icon,
Jun Aokic Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan
,
Satoshi Koyamab Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
,
Hiroyuki Takahashib Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, JapanORCID Iconhttps://orcid.org/0000-0001-5188-9063
ORCID Icon,
Yuki Nakajimab Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
,
Hiroyoshi Kunimotoa Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan;b Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
,
Takayoshi Tachibanad Department of Hematology, Kanagawa Cancer Center, Yokohama, JapanORCID Iconhttps://orcid.org/0000-0002-7780-4459
ORCID Icon,
Takuya Miyazakib Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
,
Kenji Matsumotob Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
,
Masatsugu Tanakad Department of Hematology, Kanagawa Cancer Center, Yokohama, JapanORCID Iconhttps://orcid.org/0000-0001-8814-230X
ORCID Icon,
Etsuko Yamazakie Department of Laboratory Medicine, Yokohama City University Hospital, Yokohama, Japan
,
Shin Fujisawac Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan
,
Heiwa Kanamorid Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan
,
Masataka Tagurif Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, JapanORCID Iconhttps://orcid.org/0000-0001-8902-0056
ORCID Icon &
Hideaki Nakajimaa Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan;b Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, JapanCorrespondence[email protected]
[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8967-4954
ORCID Icon show all
Pages 620-628 | Published online: 27 May 2022

References

  • Vardiman JW. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes/JW Vardiman, J. Thiele, D. Arber. Blood. 2009;114:937–951.
  • Malcovati L, Hellström-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943–2964.
  • de Witte T, Hagemeijer A, Sucio S, et al. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European intergroup trial. Haematologica. 2010;95:1754–1761.
  • Basquiera AL, Rivas MM, Remaggi G, et al. Allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndrome: Experience of the argentinean group of bone marrow transplantation (GATMO). Hematology. 2015;21:162–169.
  • Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2012;104:579–585.
  • Platzbecker U, Schetelig J, Finke J, et al. Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biol Blood Marrow Transplant. 2012;18:1415–1421.
  • Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)– specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–2919.
  • Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091–2101.
  • Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.
  • Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–2465.
  • Lee JH, Lee JH, Lim SN, et al. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity. Bone Marrow Transplant. 2010;45:450–457.
  • Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376:536–547.
  • Patel SS, Sekeres MA, Nazha A. Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure. Leuk Lymphoma. 2017;58:2532–2539.
  • Germing U, Hildebrandt B, Pfeilstöcker M, et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia. 2005;19:2223–2231.
  • Della Porta MG, Alessandrino EP, Bacigalupo A, et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS strati fi ed according to the revised IPSS-R. Blood. 2014;123:2333–2343.
  • Casalegno-Garduño R, Schmitt A, Spitschak A, et al. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation. Int J Cancer. 2016;138:1792–1801.
  • Gatto S, Ball G, Onida F, et al. Contribution of β-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS). Blood. 2003;102:1622–1625.
  • Armand P, Gibson CJ, Cutler C, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012;120:905–913.
  • Baron F, Ruggeri A, Beohou E, et al. RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. Oncotarget. 2016;7:43027–43038.
  • Shaffer BC, Ahn KW, Hu Z-H, et al. Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. J Clin Oncol. 2016;34:1864–1871.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.